Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic hematopoietic cell transplantation with non-myeloablative TLI/ATG for refractory triple-negative breast cancer
2008-006262-28Phase 2Terminated
- Sponsor
- European Institute of Oncology
- Start
- Apr 2009
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mycophenolic acid and antithymocyte globulin rabbit in breast cancer, sponsored by European Institute of Oncology. Primary endpoint: Progression-free survival at 6 months. Started Apr 2009; status: terminated.
02
Drugs
mycophenolic acidantithymocyte globulin rabbit
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-006262-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006262-28.